暂无数据
代码股票名称
最新价涨跌额涨跌幅成交量成交额今开昨收最高最低总市值流通市值总股本流通股本5日涨跌幅10日涨跌幅20日涨跌幅60日涨跌幅120日涨跌幅250日涨跌幅年初至今涨跌幅股息率TTM换手率市盈率TTM市盈率(静)振幅所属行业
美股市场个股详情
CLLS Cellectis
- 2.560
- 0.0000.00%
收盘价 04/30 16:00 (美东)
- 2.560
- 0.0000.00%
盘后 16:29 (美东)
1.84亿总市值-1446市盈率TTM
2.560最高价2.500最低价9080股成交量2.520今开2.560昨收2.29万成交额0.02%换手率亏损市盈率(静)7195.35万总股本3.77452周最高2.18市净率1.10亿流通值0.96352周最低--股息TTM4308.50万流通股50.000历史最高--股息率TTM2.34%振幅0.963历史最低2.523平均价1股每手
全部分时
- 5日
- 日K
- 周K
- 月K
- 季K
- 年K
资金分布
单位: --
资金流向
实时日周月
暂无数据
新闻
分析师提供有关医疗保健公司的见解：Healthequity（HQY）、Cellectis SA（CLLS）和Idexx实验室（IDXX）
巴克莱银行仍然是Cellectis SA（CLLS）的获得买入评级
快讯 | Cellectis2023年第四季度GAAP每股收益（0.64美元）未达到预期（0.26美元），销售额为19.9亿美元，未达到1626.3万美元的预期
Cellectis认为，Cash Runway将延长至2025年第三季度，在合并财务报表发布后，将能够运营至少12个月
Cellectis认为，Cash Runway将延长至2025年第三季度，在合并财务报表发布后，将能够运营至少12个月
Cellectis 第四季度亏损/64c >CLLS
Cellectis 第四季度亏损/64c >CLLS
新闻稿：Cellectis公布了2023年第四季度和全年财务业绩
Cellectis 公布了 2023 年第四季度和全年财务业绩--在美国发布的 NATHALI-01 的初步结果和 BALLI-01 I 期临床研究的最新结果
评论
$Cellectis(CLLS.US$
NEWS
Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs
Cellectis presents novel TALEN editing processes enabling highly efficient gene correction and gene insertion in HSPCs, showcasing the potential and versatility of the technology for gene therapy. The company will present first data exploring these processes at ASGCT. The editing approaches could revolutionize the treatment of metabolic and neurologica...
NEWS
Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs
Cellectis presents novel TALEN editing processes enabling highly efficient gene correction and gene insertion in HSPCs, showcasing the potential and versatility of the technology for gene therapy. The company will present first data exploring these processes at ASGCT. The editing approaches could revolutionize the treatment of metabolic and neurologica...
$Cellectis(CLLS.US$
NEWS
Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs
Cellectis (NASDAQ: CLLS) announces a breakthrough in gene-editing therapy with the publication of a new research paper. The study demonstrates the potential of TALEN-mediated intron editing in HSPCs for targeted transgene expression, offering new treatment possibilities for metabolic and neurological diseases.
NEWS
Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs
Cellectis (NASDAQ: CLLS) announces a breakthrough in gene-editing therapy with the publication of a new research paper. The study demonstrates the potential of TALEN-mediated intron editing in HSPCs for targeted transgene expression, offering new treatment possibilities for metabolic and neurological diseases.
1
$Cellectis(CLLS.US$ Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs
3 MINUTES AGO, 4:30 PM EDT
VIA GLOBENEWSWIRE
NEW YORK, April 10, 2024 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a new research paper in Molecular Therapy, demonstrating that...
3 MINUTES AGO, 4:30 PM EDT
VIA GLOBENEWSWIRE
NEW YORK, April 10, 2024 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a new research paper in Molecular Therapy, demonstrating that...
Jean Pierre Garnier, Cellectis Chairman, thanked shareholders for supporting the Additional Investment and welcomed Mr. Dunoyer and Dr. Rivers to the board, praising their pharma industry experience.
1
$Cellectis(CLLS.US$ 今天会见到4块吗😎
阅读更多
分析
目标价预测
暂无数据
热议
美股
综合热度
股票代码
最新价
涨跌幅